BeyondSpring Pharmaceuticals
BYSI · Nasdaq · United States
Share price · BYSI
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BYSI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Nov 2026-22.9%
Nothing announced by BYSI that day or the session before.
- 2 Nov 2026+25.2%
Nothing announced by BYSI that day or the session before.
- 30 Oct 2026+24.6%
Nothing announced by BYSI that day or the session before.
- 29 Sep 2026-31.0%
- 28 Sep 2026+44.1%
Nothing announced by BYSI that day or the session before.
- 10 Sep 2026+22.0%
Nothing announced by BYSI that day or the session before.
- 17 Aug 2026-15.2%
- 14 Aug 2026-15.8%
- 13 Aug 2026+34.3%
- Day beforeEarnings date (period ending 2026-06-30)
- 10 Aug 2026-9.7%
Nothing announced by BYSI that day or the session before.
Share of unusual movement by asset
For each asset, the share of BYSI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Beta-tubulin (colchicine-site-adjacent binding site) / GEF-H1Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (1)
June 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (9)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $1.0M | $2.7M+ $3.8M short-term inv. | $0.8M-$3.8M operating cash flow | report ↗ |
View 8 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $0 | $1.1M | $4.0M+ $3.8M short-term inv. | $2.2M-$3.3M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $1.0M | $12M+ $0.1M short-term inv. | $1.5M-$4.2M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $1.0M | $9.5M | $1.8M-$5.9M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $0.9M | $6.5M+ $2.0M short-term inv. | —-$4.2M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $0.6M | — | $2.1M-$5.2M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $0.8M | $8.4M+ $6.0M short-term inv. | $4.0M-$7.0M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $0.7M | — | $3.2M-$5.3M operating cash flow | report ↗ |
| 2021-Q3 | $0.3M | $8.5M | $63M+ $28M short-term inv. | $18M$2.8M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $4.4M | $7.8M+ $4.8M short-term inv. | $0.3M-$20M operating cash flow | report ↗ |
BeyondSpring reported revenue of $0M, unchanged YoY, with R&D spend of $4.39M, up 66.3% YoY. Cash and equivalents stood at $7.79M at year-end 2025. Net income/loss was not disclosed, and the quarterly net burn was $1.01M.
The company is advancing Plinabulin, its lead asset, including a planned NDA submission with China’s NMPA and a confirmatory global Phase 3 study in second- and third-line non-squamous NSCLC after progression on immune checkpoint inhibitors. Investigator-initiated studies in checkpoint-inhibitor-progressed cancers and first-line extensive-stage small cell lung cancer are ongoing. Its affiliate SEED Therapeutics advanced a novel RBM39 degrader into Phase 1 clinical studies in January 2026, supported by collaborations with Eli Lilly and Eisai.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0 | $2.6M | $2.9M+ $0 short-term inv. | $2.8M-$16M operating cash flow | report ↗ |
| 2023-FY | $0 | $7.3M | $7.8M+ $0.2M short-term inv. | $5.3M-$16M operating cash flow | report ↗ |
| 2022-FY | $1.4M | $26M | $34M+ $2.9M short-term inv. | $8.3M-$27M operating cash flow | report ↗ |
| 2021-FY | $1.4M | $37M | $42M+ $31M short-term inv. | $16M-$47M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-07-01 | Qiu Min · Chief Executive Officer | Award / grant (derivative) | 100,000 | — | — | Form 4 |
| 2026-07-01 | Majeti Jiangwen · director | Award / grant (derivative) | 100,000 | — | — | Form 4 |
| 2026-04-01 | Kirkby Matthew · director | Award / grant (derivative) | 23,902 | — | — | Form 4 |
| 2026-04-01 | Xu Sihai · director | Award / grant (derivative) | 18,689 | — | — | Form 4 |
| 2026-04-01 | Huang Lan · director, Chief Executive Officer, 10% owner | Award / grant (derivative) | 11,514 | — | — | Form 4 |
| 2026-04-01 | Lu Yingjuan June · Chief Scientific Officer | Award / grant (derivative) | 17,840 | — | — | Form 4 |
| 2026-04-01 | Majeti Jiangwen · director | Award / grant (derivative) | 21,730 | — | — | Form 4 |
| 2026-04-01 | Delaney Brendan · director | Award / grant (derivative) | 20,427 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 20 reporting institutions held 6.0M shares ($9.8M, 14.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Decheng Capital LLC | 3,800,702 | $6.2M |
| 2 | BlackRock, Inc. | 649,462 | $1.1M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 607,934 | $997K |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 375,371 | $616K |
| 5 | STATE STREET CORP | 231,120 | $379K |
| 6 | VANGUARD FIDUCIARY TRUST CO | 179,925 | $295K |
| 7 | NORTHERN TRUST CORP | 69,268 | $114K |
| 8 | Meridian Wealth Management, LLC | 15,000 | $25K |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 11,100 | $18K |
| 10 | Vanguard Global Advisers, LLC | 4,802 | $8K |
| 11 | MORGAN STANLEY | 4,570 | $7K |
| 12 | NATIONAL BANK OF CANADA /FI/ | 2,875 | $5K |
| 13 | Trifecta Capital Advisors, LLC | 1,500 | $2K |
| 14 | UBS Group AG | 1,170 | $2K |
| 15 | Tower Research Capital LLC (TRC) | 1,011 | $2K |